Biologically Active HIV-1 Tat Protein Production via Logarithmic Phase Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV vaccine development efforts have been hindered by the high variability of the Envelope protein, leading to ineffective neutralizing antibodies and failure in preventing infection, and recent approaches targeting other HIV antigens have also shown limited success in controlling virus replication and disease progression.
Innovation Solution
The production of biologically active HIV-1 Tat protein, which is a key regulatory protein involved in viral replication and pathogenesis, as a vaccine candidate, inducing both neutralizing antibodies and T-cell responses, and acting as an immunomodulatory adjuvant to enhance immune responses to other antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HIV vaccine approaches target the Envelope protein to generate neutralizing antibodies, then sterilising immunity is pursued, but the high variability of Env prevents effective recognition of conformational epitopes and leads to vaccine failure
Solution Approach 1:
The patent extracts the Tat protein from the HIV virus as a vaccine candidate, separating it from the problematic variable Envelope protein. Tat is a conserved regulatory protein essential for viral replication, and its extraction as a standalone antigen avoids the variability issues of Env while maintaining immunogenicity and protective potential
2Productivity
If Tat protein is produced in E. coli using conventional induction methods, then high yield is achieved, but the protein forms inclusion bodies and aggregates, requiring complex refolding procedures
Solution Approach 1:
The patent changes the induction parameters by using autoinduction conditions where the culture medium composition itself triggers protein expression. This approach, combined with specific growth phase control and temperature optimization, enables high-level soluble Tat production without inclusion body formation, eliminating complex refolding steps while maintaining high yield
3Reliability
If Tat protein is produced at high concentration to ensure sufficient vaccine antigen, then immunogenicity is enhanced, but protein aggregation and loss of biological activity occur
Solution Approach 1:
The patent employs dynamic control of protein expression by inducing Tat production at specific growth phases and using inducible promoters that allow temporal regulation. This dynamic approach enables the protein to be produced at optimal concentrations that maintain solubility and correct folding, preventing aggregation while ensuring sufficient antigen levels for immunogenicity
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
Tat protein produced in bulk culture is inactive when induced at conventional optical densities but can be obtained in biologically active form when induced during the logarithmic growth phase.